Mark Leid

Title: Mark Leid: Innovator in Cancer Research

Introduction

Mark Leid is a prominent inventor based in Corvallis, OR (US). He has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of squamous cell carcinoma. With a total of 3 patents, his work has the potential to impact the lives of many patients.

Latest Patents

One of Mark Leid's latest patents focuses on "CTIP2 expression in squamous cell carcinoma." This patent provides methods for diagnosing and staging squamous cell carcinomas, such as head and neck squamous cell carcinoma (HNSCC), by detecting the expression of chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2). The findings demonstrate that CTIP2 expression is increased in SCC compared to normal samples. Additionally, the patent includes kits for detecting SCC and methods for identifying CTIP2 inhibitors. Another significant patent is related to the "Induction of apoptosis in cancer cells." This invention offers compounds that induce or inhibit apoptosis preceded by cell-cycle arrest. It also provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer.

Career Highlights

Throughout his career, Mark Leid has worked at notable institutions, including the Burnham Institute. His research has focused on innovative approaches to cancer treatment and diagnosis, showcasing his dedication to advancing medical science.

Collaborations

Mark Leid has collaborated with esteemed colleagues such as Joseph A Fontana and Ling Jong. These partnerships have contributed to the development of his groundbreaking patents and research.

Conclusion

Mark Leid's contributions to cancer research through his patents and collaborations highlight his commitment to improving patient outcomes. His innovative work continues to pave the way for advancements in the diagnosis and treatment of cancer.